Press Releases argenx SE

Equities

ARGX

NL0010832176

Market Closed - Euronext Bruxelles Other stock markets 11:35:00 2024-04-26 am EDT			5-day change	1st Jan Change
349.3 ^EUR	+0.90%		+3.56%	+1.69%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	Apr. 16	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	Apr. 16	GL
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	Mar. 28	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	Mar. 27	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	Mar. 27	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	Mar. 27	GL
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	Mar. 26	GL
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	GL
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	Mar. 08	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	Mar. 07	GL
Argenx : argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	Feb. 29	PU
Argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	Feb. 29	GL
Argenx to Present at Upcoming Investor Conferences	Feb. 26	GL
Argenx to Present at Upcoming Investor Conferences	Feb. 26	AQ
Argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024	Feb. 22	GL
Argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024	Feb. 22	AQ
Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	Feb. 20	GL
Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	Feb. 20	AQ
Argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	Jan. 18	GL
Argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	Jan. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases argenx SE

Equities

ARGX

NL0010832176

Press Releases

Filters